ForCast Orthopedics

Executive Summary

ForCast Orthopedics is a development-stage medical device company addressing the significant unmet need in periprosthetic joint infection (PJI), a devastating complication of joint replacement surgery. Current standard-of-care involves systemic antibiotics and often revision surgery, with poor outcomes due to biofilm resistance. ForCast's proprietary platform delivers targeted antibiotic therapy directly to the infected implant site, potentially eradicating biofilm and improving patient outcomes while reducing systemic toxicity. The company's approach represents a paradigm shift in managing PJI, a market expected to grow as joint replacement procedures increase globally. Though still in early development, ForCast Orthopedics has demonstrated proof-of-concept in preclinical models. The company has not yet disclosed specific financing or clinical trial timelines, but its innovative technology has attracted interest from key opinion leaders. Success will depend on securing additional funding, navigating regulatory pathways, and generating robust clinical data. With a focused strategy and a compelling value proposition, ForCast Orthopedics is well-positioned to become a leader in targeted infection therapeutics for orthopedics.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round Closing60% success
• H1 2026Preclinical Study Results Publication70% success
• Q4 2026FDA Pre-Submission Meeting Initiation50% success